3-[2-(乙基氨基)乙基]吲哚 | 61-53-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-[2-(乙基氨基)乙基]吲哚
• 中文别名: N-乙基-2-(1H-吲哚-3-基)乙胺
• 英文名称: 5-fluoro-α-methyltryptamine
• 英文别名: 3-(ethylaminoethyl)indole；PAL-536；ethyl-(2-indol-3-yl-ethyl)-amine；Aethyl-(2-indol-3-yl-aethyl)-amin；N-ETHYL-2-(1H-INDOL-3-YL)ETHANAMINE；N-ethyl-tryptamine；N-Ethyltryptamine
• CAS: 61-53-0
• 化学式: C₁₂H₁₆N₂
• mdl: MFCD01718777
• 分子量: 188.272
• InChiKey: TZWUSTVNAVKAPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-[2-(乙基氨基)乙基]吲哚 在 三乙胺 、 potassium hydroxide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成
  参考文献：
  名称：

  通过分子内[3 + 2]环加成使吲哚脱芳香化：获得五价骨架的Strychons生物碱的五环骨架。

  摘要：

  描述了一种通过串联的1,2-酰氧基迁移/分子内[3 + 2]环加成过程使吲哚脱芳香化来构建各种多取代的多环吲哚啉环化的中型至中型环的有效方法。士的宁的五环骨架可以通过这种串联环加成反应和进一步的曼尼希反应合成。这种方法将提供一种新的策略来合成拟苯丙酸杆菌生物碱。

  DOI：

  10.1021/acs.orglett.8b01720
• 作为产物：
  描述：

  吲哚-3-乙醛酰氯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 18.0h， 生成 3-[2-(乙基氨基)乙基]吲哚
  参考文献：
  名称：

  Alpha-ethyltryptamines as dual dopamine–serotonin releasers

  摘要：

  The dopamine (DA), serotonin (5-HT), and norepinephrine (NE) transporter releasing activity and serotonin-2A (5-HT2A) receptor agonist activity of a series of substituted tryptamines are reported. Three compounds, 7b, (+)-7d and 7f, were found to be potent dual DA/5-HT releasers and were > 10-fold less potent as NE releasers. Additionally, these compounds had different activity profiles at the 5-HT2A receptor. The unique combination of dual DA/5-HT releasing activity and 5-HT2A receptor activity suggests that these compounds could represent a new class of neurotransmitter releasers with therapeutic potential. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.07.062
• 作为试剂：
  描述：

  3-[2-(乙基氨基)乙基]吲哚 、 methyl 2,5-dioxopentanoate 在 3-[2-(乙基氨基)乙基]吲哚 作用下， 生成
  参考文献：
  名称：

  Indole derivatives and therapeutically acting drugs

  摘要：

  本发明涉及新的吲哚衍生物、它们的制备和用作药物。所述化合物可以用一般式表示 ##STR1## 其中R代表氢原子或烷基或苄基基团，Z代表氢原子或卤素原子或烷基、羟基、酰氧基、氨基甲酸酯或甲氧基基团。它们是通过将色胺衍生物与公式的合成物反应而制备的。##STR2## 在此公式中，X和Y分别代表氧原子或硫原子，R.sub.1和R.sub.2分别代表烷基或苯基基团或形成一个烷基亚甲基链。它们可以作为化学合成的中间体化合物，也可以作为治疗脑血管和心血管功能不足的药物。

  公开号：

  US04200638A1

文献信息

• [EN] PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES<br/>[FR] DÉRIVÉS DE PHÉNÉTHYLAMIDE ET LEURS ANALOGUES HÉTÉROCYCLIQUES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2010044054A1

  公开（公告）日：2010-04-22

  The invention relates to novel phenethylamide derivatives and their heterocyclic analogues of formula (I), wherein A, B, R1, R2 and R3 are as described in the application, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

  这项发明涉及新型苯乙酰胺衍生物及其异环类似物，其化学式为(I)，其中A、B、R1、R2和R3如申请中所述，并且涉及将这种化合物或这种化合物的药用可接受盐用作药物，特别是促进睡眠的药物受体拮抗剂。
• Solid Support for Fmoc-Solid Phase Synthesis of Peptides
  申请人：SRIVASTAVA KRIPA S.

  公开号：US20090131587A1

  公开（公告）日：2009-05-21

  The present invention provides compositions and processes for the solid phase synthesis of polypeptides. In particular, the present invention provides solid supports and processes for preparing solid supports for the synthesis of polypeptides.

  本发明提供了多肽的固相合成的组合物和工艺。具体地，本发明提供了固相支持体和用于制备固相支持体的工艺，用于合成多肽。
• Azepino [1,2,3-lm]-.beta.-carboline compounds and pharmaceutical
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US04228168A1

  公开（公告）日：1980-10-14

  An azepino[1,2,3-lm]-.beta.-carboline compound of the formula: ##STR1## wherein R.sup.1 is hydrogen, cycloalkyl of 3 to 7 carbon atoms, phenyl, hydroxy, alkoxycarbonyl of 2 or 3 carbon atoms or alkanoyl of 2 or 3 carbon atoms, and A is single bond or straight or branched alkylene of one to 5 carbon atoms. Several methods of preparing the compound [I] are disclosed. The compound [I] and a pharmaceutical acceptable acid addition salt thereof have a potent anti-anoxic activity.

  一种azepino[1,2,3-lm]-β-咔啉类化合物，化学式如下：##STR1##其中R.sup.1为氢、3至7个碳原子的环烷基、苯基、羟基、2或3个碳原子的烷氧羰基或2或3个碳原子的烷酰基，A为单键或一至5个碳原子的直链或支链烷基。公开了制备化合物[I]的几种方法。化合物[I]及其药用可接受的酸加盐具有强效的抗缺氧活性。
• Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
  申请人：——

  公开号：US20030078271A1

  公开（公告）日：2003-04-24

  This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.

  这项发明涉及嘧啶和吲哚酮衍生物，它们是选择性GAL3受体拮抗剂。该发明提供了一种包含该发明化合物的治疗有效量和药用载体的药物组合物。该发明还提供了通过结合该发明化合物的治疗有效量和药用载体制备的药物组合物。该发明进一步提供了一种制备药物组合物的方法，包括结合该发明化合物的治疗有效量和药用载体。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者施用足以治疗受试者抑郁症和/或焦虑症的该发明化合物的量。该发明还提供了一种治疗受试者抑郁症和/或焦虑症的方法，包括向受试者施用包含药用载体和治疗有效量GAL3受体拮抗剂的组合物。
• GAL3 antagonists for the treatment of neuropathic pain
  申请人：——

  公开号：US20040092570A1

  公开（公告）日：2004-05-13

  This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor and are useful for the treatment of neuropathic pain and other abnormalities. This invention also provides a method of treating a subject suffering from an abnormality which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's abnormality. This invention also provides a method of treating an abnormality in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.

  这项发明涉及嘧啶和吲哚酮衍生物，它们是选择性的GAL3受体拮抗剂，可用于治疗神经病痛和其他异常。这项发明还提供了一种治疗患有异常的受试者的方法，包括向受试者投予本发明中的化合物的有效剂量以治疗受试者的异常。这项发明还提供了一种治疗受试者异常的方法，包括向受试者投予包含药用载体和治疗有效量的GAL3受体拮抗剂的组合物。